Regeneron stock holds its ground as sales and earnings stay strong

Regeneron Pharmaceuticals (ISIN US75886F1075) remains a closely watched large-cap biotech name as its latest reported figures continue to frame the stock's valuation. The company reported annual revenue of $14.2 billion in fiscal 2025, up from $13.1 billion in fiscal 2024, while diluted earnings per share rose to $39.52 from $37.05 over the same period.

Revenue tops $14 billion

Regeneron stock is anchored by a business that generated $14.2 billion in fiscal 2025, according to the companys latest annual report, after $13.1 billion in fiscal 2024. That 8.4% increase gives investors a concrete baseline for the shares as they trade against a still-expanding top line.

Gross margin also stayed high at 86.7% in fiscal 2025, compared with 87.2% a year earlier, showing only a slight step down even as revenue increased. The companys reported cash and marketable securities stood at $16.4 billion at 31 December 2025, a balance-sheet figure that matters in a capital-intensive drug pipeline business.

EPS and margin stay high

Regeneron reported diluted EPS of $39.52 for fiscal 2025, versus $37.05 in fiscal 2024, which means earnings rose by 6.7% year over year. Net income reached $4.3 billion in fiscal 2025, compared with $4.1 billion in fiscal 2024, underlining the same pattern of steady profitability.

The operating picture is still tied to key medicine franchises, with Dupixent collaboration revenue, Eylea family sales and other immunology and ophthalmology products driving the mix. For market readers, the combination of double-digit billions in revenue and high-80s gross margin is the more important lens than day-to-day noise.

Dupixent and Eylea matter

Dupixent remains one of the most important commercial references for the company because it supports the wider operating base around Regenerons ophthalmology and immunology exposure. Eylea family revenue is also central to the stock because it helps determine whether the company can keep converting product demand into cash generation.

That matters after fiscal 2025 operating income of $4.1 billion, up from $3.8 billion in fiscal 2024, showed that the business still converts sales into profit at a high rate. In a sector where pipeline setbacks can quickly alter sentiment, the combination of $14.2 billion in revenue and $4.3 billion in net income remains the key numerical anchor.

Shares near the market lens

For investors, the stock is best read through its latest reported fundamentals and any live market level on Nasdaq, where Regeneron is listed. The share price and market capitalization are the most direct market checks, but the operational story remains the stronger part of the current case.

Dupixent franchise

Dupixent is the representative product line that best captures how Regeneron monetizes its research base, even though much of the franchise is shared through a collaboration structure. Its importance is visible in the scale of the broader company results, which reached $14.2 billion in fiscal 2025 revenue and $4.3 billion in net income.

Stock and valuation

Regeneron stock closes this article as a fundamentals-led biotech name whose latest reported figures show $14.2 billion in fiscal 2025 revenue, $39.52 in diluted EPS and $16.4 billion in cash and marketable securities at 31 December 2025. Those are the figures that define the valuation debate more clearly than any short-term narrative.